Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

506
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
506
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

5.1K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
5.1K
Antibiotic Selection00:57

Antibiotic Selection

56.6K
Overview
56.6K
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

32
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
32
Urinary Tract Infection IV: Nursing Management01:17

Urinary Tract Infection IV: Nursing Management

127
In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs...
127
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

526
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
526

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Strengths and weaknesses of computerized clinical decision support systems: insights from a digital control center (C3 COVID-19) for early and personalized treatment for COVID-19.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2024
Same author

Recommendations on the use of azole antifungals in hematology-oncology patients.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2023
Same author

COVID-19 in donation and transplant.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2022
Same author

Mechanism of action of cefiderocol.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2022
Same author

Cefiderocol. Summary and conclusions.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2022
Same author

Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2022
Same journal

Nasal swab-guided deescalation of empirical linezolid in respiratory infections at a secondary-level hospital: quantification of quality gaps and antimicrobial stewardship opportunities.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

[Infectious complications following intravesical bacillus Calmette-Guérin therapy: a case series].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

Long-term persistence, effectiveness, safety, and metabolic impact of bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in people living with HIV in the BICTARG cohort.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

Associations between high-risk human papillomavirus genotypes: evidence of HPV16 predominance as a monoinfection and its no stronger link with high-grade lesions.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

Pediatric septic arthritis caused by <i>Staphylococcus argenteus</i>.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

[Colonisation or early invasion? Disseminated aspergillosis after bronchial isolation of <i>Aspergillus fumigatus</i> in a heart transplant recipient].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
See all related articles

Related Experiment Video

Updated: Oct 18, 2025

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.0K

Ceftazidime-avibactam.

M Matesanz1, J Mensa

  • 1Mayra Matesanz, Hospital at Home Unit. Department of Internal Medicine. Hospital clínico San Carlos. Madrid. Spain. mayra.matesanz@salud.madrid.org.

Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia
|October 2, 2021
PubMed
Summary
This summary is machine-generated.

Ceftazidime-avibactam effectively treats infections caused by Pseudomonas aeruginosa and many Enterobacteriaceae, including those with extended-spectrum beta-lactamases. Resistance can emerge but often restores susceptibility to other antibiotics like meropenem.

More Related Videos

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.0K
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.5K

Related Experiment Videos

Last Updated: Oct 18, 2025

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.0K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.0K
Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.5K

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Ceftazidime, a third-generation cephalosporin, exhibits activity against Pseudomonas aeruginosa.
  • Avibactam inhibits beta-lactamases, including class A, C, and some D types.
  • The combination of ceftazidime-avibactam broadens the antibacterial spectrum.

Purpose of the Study:

  • To evaluate the antibacterial spectrum of ceftazidime-avibactam.
  • To investigate mechanisms of resistance development to ceftazidime-avibactam.
  • To assess the clinical implications of ceftazidime-avibactam treatment.

Main Methods:

  • Antimicrobial susceptibility testing against various bacterial isolates.
  • Analysis of beta-lactamase mutations in resistant strains.
  • Review of clinical data on colonization periods.

Main Results:

  • Ceftazidime-avibactam covers 95% of P. aeruginosa and >99% of Enterobacteriaceae, including ESBL-producing strains.
  • Resistance mutations in Klebsiella pneumoniae and Enterobacter cloacae involve amino acid changes in the beta-lactamase Ω-loop.
  • Resistant strains often regain susceptibility to meropenem.
  • Treatment with ceftazidime-avibactam may shorten colonization periods for multidrug-resistant organisms.

Conclusions:

  • Ceftazidime-avibactam is a valuable therapeutic option for infections caused by susceptible Gram-negative bacteria.
  • Understanding resistance mechanisms is crucial for optimizing treatment strategies.
  • The drug may reduce the burden of multidrug-resistant organism colonization.